Bone marrow transplantation for hematologic malignancies: the Stanford experience.
Allogeneic and autologous BMTs are highly effective and successful treatment modalities for selected patients. Use of BMT earlier in the course of disease yields better results when compared to patients with more advanced disease. Recent advances such as use of cloned growth factors, cytokines, etc..., will continue to contribute to lessen morbidity and mortality. Finally, as investigators understand, prevent, and treat expected side effects from BMTs, the patients' burden in terms of physical, psychological, and financial costs should lessen substantially.
Chao
N J
NJ
Department of Medicine, Stanford University Medical Center, California.
Amylon
M D
MD
Long
G D
GD
Negrin
R S
RS
Hoppe
R T
RT
Horning
S J
SJ
Blume
K G
KG
D000328:Adult; D000741:Anemia, Aplastic / Q000601:surgery; D016026:Bone Marrow Transplantation / Q000276:immunology; D002140:California; D002648:Child; D005260:Female; D006801:Humans; D007165:Immunosuppression Therapy / Q000379:methods; D007938:Leukemia / Q000601:surgery*; D008228:Lymphoma, Non-Hodgkin / Q000601:surgery*; D008297:Male; D012189:Retrospective Studies; D013789:Thalassemia / Q000601:surgery; D014182:Transplantation, Autologous; D014184:Transplantation, Homologous